Antiviral Prophylaxis in Transplantation
On this page
Direct answer
Cytomegalovirus dominates the post-transplant infection calendar, and its prevention runs on two strategies: universal prophylaxis with valganciclovir 900 mg once daily for three to six months in high-risk pairings — most importantly a seropositive donor with a seronegative recipient (D+/R-) — or pre-emptive therapy, where weekly PCR monitoring treats replication before disease appears. Valganciclovir's dose-limiting toxicity is myelosuppression, so the full blood count is checked weekly, and the dose falls with creatinine clearance. Herpes simplex and varicella-zoster receive aciclovir prophylaxis through the early immunosuppression period; hepatitis B surface antigen-positive transplant recipients take nucleos(t)ide analogues indefinitely; Pneumocystis prophylaxis is cotrimoxazole. In the Indian transplant patient, tuberculosis steals the interaction spotlight: rifampicin from the national anti-tubercular regimen induces tacrolimus and cyclosporine metabolism so powerfully that tacrolimus doses may need several-fold increases under level-guided monitoring — the single most consequential prescribing collision in Indian transplant medicine.
What you must remember
- Highest CMV risk: donor positive, recipient negative (D+/R-); seropositive recipients carry intermediate risk from reactivation under immunosuppression, particularly after lymphocyte-depleting agents.
- Valganciclovir 900 mg daily (900 mg twice daily as pre-emptive treatment dosing; 5 mg/kg intravenous ganciclovir equivalent where tablets cannot be used): renal dose adjustment is mandatory — 450 mg daily below a creatinine clearance of about 40 mL/min.
- Myelosuppression: leucopenia, anaemia, thrombocytopenia — weekly full blood counts; hold or dose-reduce rather than abandon; foscarnet is the marrow-sparing alternative at the cost of nephrotoxicity and electrolyte disturbances including ionised calcium falls.
- Pre-emptive strategy: weekly CMV PCR for 3-4 months, treating asymptomatic replication at a threshold viral load — equal outcomes to universal prophylaxis in many programmes, less drug exposure.
- HSV/VZV: aciclovir or valaciclovir prophylaxis during the highest immunosuppression months; live vaccines (measles, varicella, yellow fever) are contraindicated post-transplant — inactivated influenza vaccination is routine.
- Hepatitis B: antiviral prophylaxis with lamivudine, entecavir or tenofovir in HBsAg-positive recipients, with anti-HBs monitoring; indefinite therapy for high-risk profiles.
- Pneumocystis jirovecii: cotrimoxazole prophylaxis, dose-adjusted for renal function and continued months to years by programme protocol.
- The Indian interaction: rifampicin under NTEP therapy can cut tacrolimus levels by 70-90%, requiring enormous dose escalation with level monitoring, or substitution strategies; the transplant physician co-manages every tuberculosis course.
The first three months of a kidney transplant
A 41-year-old receives a deceased-donor kidney; the donor is CMV seropositive, he is seronegative — the highest-risk pairing. Valganciclovir 900 mg daily begins within days, adjusted to 450 mg when his creatinine clearance sits in the low 40s, alongside cotrimoxazole three times weekly and his tacrolimus-mycophenolate-prednisolone baseline. At week six his white count falls to 2.1 — a predictable valganciclovir effect; the dose is held for a week with granulocyte support, then resumed at reduced strength, and the count recovers. The programme runs to 200 days of prophylaxis for this pairing, after which monthly clinical surveillance continues.
The contrasting programme down the corridor runs pre-emptive: seropositive recipient, low-risk donor, weekly PCR drawn with the routine bloods, and valganciclovir 900 mg twice daily started only when the viral load crosses the treating threshold — the same drug, used as a scalpel rather than a blanket, sparing months of marrow exposure. Either programme is defensible; what is not defensible is untreated D+/R- risk, which the exam presents as a stem and expects the candidate to escalate.
Where students slip
Strategy vocabulary is slip one: "prophylaxis" means everyone at risk receives the drug for a fixed period; "pre-emptive" means monitoring-driven treatment of asymptomatic replication — stems swap the words and expect the candidate to notice. Slip two is toxicity-matching: leucopenia on valganciclovir is managed by dose adjustment and monitoring, not by switching to foscarnet reflexively (foscarnet exchanges marrow safety for nephrotoxicity and hypocalcaemia). The third is the Indian signature: any transplant stem mentioning anti-tubercular therapy is testing the rifampicin-tacrolimus interaction, and the expected answer involves level-guided dose escalation or regimen adjustment, never passive continuation.
Frequently asked questions
Which transplant pairing carries the highest cytomegalovirus risk?
Donor seropositive with recipient seronegative (D+/R-), because the recipient has no immunity and receives latent virus with the organ.
What is the standard valganciclovir prophylaxis regimen?
900 mg once daily for three to six months (about 200 days in high-risk kidney transplantation), reduced to 450 mg daily at a creatinine clearance below about 40 mL/min.
How do prophylaxis and pre-emptive strategies differ?
Prophylaxis gives antiviral to all at-risk patients for a fixed period; pre-emptive therapy monitors CMV PCR weekly and treats only when replication crosses a threshold before disease.
Which drug interaction defines tuberculosis therapy in a transplant recipient?
Rifampicin powerfully induces tacrolimus and cyclosporine metabolism, collapsing drug levels unless doses are escalated several-fold under concentration monitoring.
Which vaccines are contraindicated after transplantation?
Live vaccines — measles, varicella, yellow fever — while on significant immunosuppression; inactivated vaccines such as influenza are given routinely.